MISSISSAUGA, ON, Nov. 20, 2025 (GLOBE NEWSWIRE) — BioSyent Inc. (BioSyent, TSX Venture: RX) today released its financial results for the three months (Q3) and nine months (YTD) ended September 30, 2025. Key points include:
| (CAD) | Q3 2025 | % change compared toQ3 2024 | from the beginning of 2025 | % change compared tofrom the beginning of 2024 | Trailing twelve months (TTM) September 30, 2025 |
% change compared toTTM September 30, 2024 |
| Canadian Pharmaceutical Sales | 9 864 254 | +19% | 28 351 130 | +16% | 36 897 581 | +14% |
| International pharmaceutical sales | 1,153,742 | +94% | 3 134 572 | +316% | 3311306 | +310% |
| Sales of obsolete business | 1 203 808 | +83% | 1 894 358 | +73% | 1,967,857 | +48% |
| Total company sales | 12 221 804 | +28% | 33 380 060 | +27% | 42 176 744 | +22% |
| Bitda¹ | 3 632 399 | +27% | 9 594 195 | +35% | 11 835 307 | +35% |
| Net Income After Tax (NIAT) | 2 682 340 | +16% | 7 020 444 | +24% | 8 633 638 | +21% |
| Fully diluted earnings per share | 0.23 | +19% | 0.61 | +28% | 0.75 | +25% |
- Return on average equity for TTM as of September 30, 2025 was 22% compared to 20% for TTM as of September 30, 2024.
- During 2025, a total of 19,500 shares of common stock were repurchased for cancellation under the common issuer offering (NCIB).
- Paid quarterly cash dividends of $0.05 per common share on March 14, 2025, June 13, 2025 and September 15, 2025.
- A subsequent cash dividend of $0.05 per common share has been declared, payable on December 15, 2025.
“BioSyent delivered strong financial results in the third quarter,” commented Mr. Rene Gerum, President and CEO of BioSyent. “Each of our three divisions performed well during the quarter, with overall company sales up 28%. Although we experienced some declines in gross margin due to changes in sales mix, our overall EBITDA margin¹ in the third quarter of 2025 remained consistent with the comparable period at 30% of sales as operating expenses remained in line with sales growth. Year to date, total company sales increased 27% and EBITDA margin increased 1 of sales accounted for 29% of sales. FeraMAX® and Tibella® / Tibelia® products continue to deliver profitable sales growth both in Canada and internationally. In just one year since our acquisition of the worldwide rights to Tibella® / Tibelia® in September 2024, the product has delivered additional sales and profit growth in line with our initial expectations. As we enter the final weeks of the year, we remain focused on continuing the profitable growth and momentum of our business to. end of 2025 and in 2026.”
The CEO's presentation on the third quarter and 2025 results is available at the following link: www.biosyent.com/investors/
The Company's interim unaudited condensed consolidated financial statements and management's discussion and analysis for the three and nine months ended September 30, 2025 and 2024 will be published on the website www.sedarplus.ca November 20, 2025
For direct market quotes from the TSX Venture Exchange and other financial information about the company, visit www.tmxmoney.com.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable, growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective and have a proven track record of improving patient lives. BioSyent supports the healthcare professionals who treat these patients by promoting its products through its communities, specialties and international business units.
As of the date of this press release, the Company had 11,262,282 shares of common stock outstanding.
| BioCent Inc. | ||||||
| Interim Unaudited Condensed Consolidated Statement of Comprehensive Income | ||||||
| In Canadian dollars | Q3 2025 | Q3 2024 | % Change | from the beginning of 2025 | from the beginning of 2024 | % Change |
| Net profit | 12 221 804 | 9 556 011 | 28% | 33 380 060 | 26 234 213 | 27% |
| Cost of goods sold | 2 954 884 | 2,069,596 | 43% | 7 863 386 | 5 533 089 | 42% |
| Gross profit | 9 266 920 | 7 486 415 | 24% | 25 516 674 | 20 701 124 | 23% |
| Operating expenses and financial income/expenses | 5 617 478 | 4 511 311 | 25% | 15 965 050 | 13 169 535 | 21% |
| Net profit before tax | 3649442 | 2 975 104 | 23% | 9 551 624 | 7 531 589 | 27% |
| Tax (including deferred tax) | 967 102 | 667 210 | 45% | 2 531 180 | 1,874,679 | 35% |
| Net profit after taxes | 2 682 340 | 2 307 894 | 16% | 7 020 444 | 5 656 910 | 24% |
| Net profit after taxes as a percentage of net revenue | 22% | 24% | 21% | 22% | ||
| Bitda¹ | 3 632 399 | 2,849,636 | 27% | 9 594 195 | 7 101 900 | 35% |
| EBITDA¹% to net revenue | 30% | 30% | 29% | 27% | ||
| BioCent Inc. | ||||||
| Interim unaudited condensed consolidated statement of financial position | ||||||
| HOW TO | September 30, 2025 | December 31, 2024 | % Change | |||
| RESOURCES | ||||||
| Cash, cash equivalents and short-term investments | $ | 23 395 434 | $ | 15 940 971 | 47% | |
| Trade and other receivables | 6 277 318 | 2906829 | 116% | |||
| Inventory | 5 899 364 | 5 328 086 | 11% | |||
| Prepaid expenses and deposits | 339 938 | 201 971 | 68% | |||
| Derivative asset | – | 5790 | -100% | |||
| Loans issued – current | 57 240 | 87 433 | -35% | |||
| CURRENT ASSETS | 35 969 294 | 24 471 080 | 47% | |||
| Long-term investments | 5 400 816 | 10 103 571 | -47% | |||
| Loans issued – current | 84 003 | 141 140 | -40% | |||
| Deferred tax asset | 342 359 | 401 166 | -15% | |||
| Property and equipment | 1,039,978 | 1,200,992 | -13% | |||
| Intangible assets | 4 948 931 | 5 041 501 | -2% | |||
| TOTAL NON-CURRENT ASSETS | 11 816 087 | 16 888 370 | -30% | |||
| TOTAL ASSETS | $ | 47 785 381 | $ | 41 359 450 | 16% | |
| LIABILITIES AND SHARE CAPITAL | ||||||
| CURRENT LIABILITIES | $ | 7 106 740 | $ | 5 405 106 | 31% | |
| LONG-TERM LIABILITIES | 775 772 | 951 159 | -18 | |||
| Long term debt | – | – | 0% | |||
| Total capital | 39 902 869 | 35 003 185 | 14% | |||
| TOTAL LIABILITIES AND SHARE CAPITAL | $ | 47 785 381 | $ | 41 359 450 | 16% | |
- Ebitda is a non-IFRS financial indicator. The term EBITDA does not have a standardized meaning under International Financial Reporting Standards (IFRS) and, therefore, cannot be compared with similar measures reported by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization.
The reconciliation of EBITDA to NIAT for the three months, nine months and subsequent twelve months ended September 30, 2025 and 2024 is presented in the table below:
| Three months (3rd quarter) Ended September 30 | Nine months (from the beginning of the year) Ended September 30 | Trailing twelve months (TTM) ended 30 September | ||||
| 2025 | 2024 | 2025 | 2024 | 2025 | 2024 | |
| Ebitda | 3 632 399 | 2,849,636 | 9 594 195 | 7 101 900 | 11 835 307 | 8 752 201 |
| Add: Interest income | 231 389 | 256 890 | 621 333 | 828 498 | 881 421 | 1 170 681 |
| Minus: Depreciation – fixed assets, equipment | (66,353) | (70,298) | (201,335) | (209 107) | (273,448) | (286,071) |
| Amortization of intangible assets | (135,852) | (46,545) | (424,694) | (144,521) | (588,901) | (188,909) |
| Interest expenses | (12,141) | (14,579) | (37,875) | (45,181) | (51,846) | (61,575) |
| Income tax expenses | (967 102) | (667 210) | (2,531,180) | (1,874,679) | (3,168,895) | (2,278,626) |
| INTENTION | 2 682 340 | 2 307 894 | 7 020 444 | 5 656 910 | 8 633 638 | 7 107 701 |
For more information contact:
Mr. Rene K. Gerum
President and CEO
BioCent Inc.
E-mail: [email protected]
Phone: 905-206-0013
Internet: www.biosyent.com
This press release may contain forward-looking information or statements. The contents herein represent our judgment as of the date hereof and are subject to risks and uncertainties that could cause actual results or performance to differ materially from the forward-looking information or statements. Potential risks may include, but are not limited to, risks associated with clinical trials, product development, future revenues, operations, profitability and regulatory approvals. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
